Guardian Pharmacy holder sells 3.57M shares

Guardian Pharmacy Services director and 10% owner Thomas J. Salentine Jr. reported a large stock sale executed by an affiliated entity.

Rhea-AI Filing Summary

Guardian Pharmacy Services director and 10% owner Thomas J. Salentine Jr. reported a large stock sale executed by an affiliated entity. Bindley Capital Partners I, LLC, an entity associated with him, sold 3,570,677 shares of Class A Common Stock on March 20, 2026 at an average price of $29.6825 per share in an underwritten offering led by BofA Securities and Jefferies. Following the transaction, the filing shows 4,469,316 shares held indirectly through Bindley Capital Partners I, LLC and 35,714 shares held directly in his name.

Insights

Equity analyst

Large affiliated holder completes multi-million share secondary sale in GRDN.

The filing shows Bindley Capital Partners I, LLC, associated with director and 10% owner Thomas J. Salentine Jr., sold 3,570,677 Guardian Pharmacy Services Class A shares at $29.6825 per share on March 20, 2026. The sale occurred through an underwriting agreement with BofA Securities and Jefferies.

After the sale, reported indirect holdings remain at 4,469,316 shares, with an additional 35,714 shares held directly. This indicates a significant disposition but also a continued sizable position. Actual significance for shareholders depends on the company’s total share count and broader ownership base, which are not detailed here.

Insider Trade Summary

Net Seller: 3,570,677 shares

Net Sell 2 txns

Insider Salentine Thomas J Jr

Role Director, 10% Owner

Sold 3,570,677 shs ($105.99M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	3,570,677	$29.6825	$105.99M
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 4,469,316 shares (Indirect, By Bindley Capital Partners I, LLC); Class A Common Stock — 35,714 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated March 18, 2026, by and among the Issuer, the selling stockholders party thereto and BofA Securities, Inc. and Jefferies LLC, as representatives of the several underwriters named therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GRDN report for Thomas J. Salentine Jr.?

Guardian Pharmacy Services reported that an entity associated with director and 10% owner Thomas J. Salentine Jr. sold 3,570,677 Class A shares on March 20, 2026, at an average price of $29.6825 per share in an underwritten offering.

Who actually sold the Guardian Pharmacy Services (GRDN) shares?

The shares were sold by Bindley Capital Partners I, LLC, an entity associated with Thomas J. Salentine Jr. The filing classifies this as indirect ownership, meaning the transaction is attributed to the LLC rather than a direct personal sale by Salentine.

How many GRDN shares were sold and at what price?

The filing shows 3,570,677 shares of Guardian Pharmacy Services Class A Common Stock were sold at an average price of $29.6825 per share. This represents a multi-million share secondary sale executed through an underwriting arrangement with investment banks.

How many Guardian Pharmacy (GRDN) shares does the insider still hold after the sale?

After the sale, the filing reports 4,469,316 shares held indirectly through Bindley Capital Partners I, LLC and 35,714 shares held directly by Thomas J. Salentine Jr. These holdings indicate the insider retains a substantial ownership stake in the company.

Was the GRDN insider sale part of a broader underwritten offering?

Yes. The footnote states the 3,570,677 shares were sold under an underwriting agreement dated March 18, 2026, among Guardian Pharmacy Services, certain selling stockholders, and underwriters led by BofA Securities and Jefferies, indicating a structured secondary offering.

Does the Form 4 for GRDN show any option exercises or derivative trades?

No derivative transactions are listed in this Form 4. The derivative summary section is empty, and the only reported activity is the sale of common stock, plus a separate line reflecting direct holdings without an accompanying transaction code.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salentine Thomas J Jr

(Last) (First) (Middle)

300 GALLERIA PARKWAY SE, SUITE 800

(Street)

ATLANTA GEORGIA 30339

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardian Pharmacy Services, Inc. [ GRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/20/2026		S(1)		3,570,677	D	$29.6825	4,469,316	I	By Bindley Capital Partners I, LLC
Class A Common Stock								35,714	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A common stock, par value $0.001 per share, of Guardian Pharmacy Services, Inc. (the "Issuer"), sold pursuant to the Underwriting Agreement, dated March 18, 2026, by and among the Issuer, the selling stockholders party thereto and BofA Securities, Inc. and Jefferies LLC, as representatives of the several underwriters named therein.

	/s/ Douglas Towns, Attorney-in-Fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)